Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

• Prif Awduron: Anita Moein (Awdur), Tong Lu (Awdur), Siv Jönsson (Awdur), Jakob Ribbing (Awdur), Nastya Kassir (Awdur), Wenhui Zhang (Awdur), Gizette Sperinde (Awdur), Rong Zhang (Awdur), Meina Tang (Awdur), Young S. Oh (Awdur), Rene Bruno (Awdur), Rui Zhu (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2022-09-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Etrolizumab is an IgG1‐humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately‐to‐severely active ulcerative colitis (UC). Population pharmacokinetic (PK) analysis was performed to characte...